Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.6 USD | -4.28% | -15.84% | -26.29% |
May. 13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
May. 08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 75.86M | Sales 2025 * | 89.25M | Capitalization | 228M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -29M | EV / Sales 2024 * | 3.31 x |
Net Debt 2024 * | 22.63M | Net Debt 2025 * | 43.9M | EV / Sales 2025 * | 3.05 x |
P/E ratio 2024 * |
-6.82
x | P/E ratio 2025 * |
-7.93
x | Employees | 171 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.19% |
Latest transcript on NeuroPace, Inc.
1 day | -4.28% | ||
1 week | -15.84% | ||
Current month | -41.49% | ||
1 month | -45.71% | ||
3 months | -50.36% | ||
6 months | -12.54% | ||
Current year | -26.29% |
Managers | Title | Age | Since |
---|---|---|---|
Joel Becker
CEO | Chief Executive Officer | 56 | 23-07-09 |
Rebecca Kuhn
FOU | Founder | 63 | 97-11-18 |
Frank Fischer
FOU | Founder | 82 | 97-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lisa Andrade
BRD | Director/Board Member | 52 | 21-10-31 |
Joseph Lacob
BRD | Director/Board Member | 68 | 97-11-18 |
Frank Fischer
FOU | Founder | 82 | 97-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 7.6 | -4.28% | 68,946 |
24-05-22 | 7.94 | -0.13% | 44,939 |
24-05-21 | 7.95 | -0.38% | 119,393 |
24-05-20 | 7.98 | -2.33% | 72,723 |
24-05-17 | 8.17 | -4.56% | 52,134 |
Delayed Quote Nasdaq, May 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.29% | 228M | |
+10.22% | 226B | |
+12.99% | 198B | |
+18.09% | 142B | |
+28.66% | 111B | |
+2.09% | 65.26B | |
+14.70% | 54.36B | |
+6.68% | 50.94B | |
+8.29% | 44.8B | |
+2.60% | 36.8B |
- Stock Market
- Equities
- NPCE Stock